IN RE: COPAXONE ANTITRUST LITIGATION

Track this case

Case Number:

2:22-cv-01232

Court:

New Jersey

Nature of Suit:

Anti-Trust

Multi Party Litigation:

Class Action

Judge:

Julien Xavier Neals

Firms

Companies

Sectors & Industries:

  1. March 03, 2025

    Teva Should Face Key Copaxone Antitrust Claims, Court Told

    Mylan and pharmaceutical wholesalers should be allowed to proceed with some, but not all, parallel claims accusing Teva of using regulatory deception, false advertising, improper rebates and more to delay generic competition to its Copaxone multiple sclerosis treatment, a special master has recommended in New Jersey federal court.

  2. March 07, 2022

    Teva Stalled Generics For Blockbuster MS Drug, Buyers Say

    Teva Pharmaceuticals was hit with a proposed class action Monday, with pharmacies and other purchasers accusing the drugmaker of unlawfully suppressing generic competition for its $3 billion-a-year multiple sclerosis treatment Copaxone by entering into exclusionary contracts and spreading misinformation about the generics.